NCT01871675View on ClinicalTrials.gov

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin LymphomaT-cell Lymphoma
Interventions
DRUG

IPI-145

DRUG

Rituximab

DRUG

Bendamustine

Trial Locations (4)

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, PLLC, Nashville

73104

Oklahoma University, Oklahoma City

80218

The Colorado Blood Cancer Institute, Denver

Sponsors
All Listed Sponsors
collaborator

Infinity Pharmaceuticals, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER